The first year of the Trump administration was kind to pharma, but it might not be so fortunate in 2018.
Alex Azar, previously a senior executive at Eli Lilly, proposed granting Part B the authority to negotiate lower prices.
The FDA's Office of Prescription Drug Promotion issued a warning letter to Amherst Pharmaceuticals and Magna Pharmaceutical.
A mini wave of state-level rule-making has thrust the issue of restrictions on pharma payments to medical professionals back into the spotlight.
The OPDP has only issued two letters in 2017, compared to 11 last year.
The lobbying group said it's unclear what the agency's goal is with this research and how it promotes public health.
Johnson & Johnson has breached the U.K.'s drug regulation code in three places in promotions for smoking cessation product Nicorette.
The Congressional Budget Office says that Sanders' bill would save the U.S. federal government nearly $7 billion over the next decade.
The FDA recently proposed studies designed to determine how disclosures in drug ads affect how viewers frame information.
The drugmaker has been handed a "public reprimand" by the U.K.'s Prescription Medicines Code of Practice Authority after the creative director of an unnamed agency used the company's patient support materials on its website.
The bill, introduced in March, is being considered as an amendment in the upcoming PDUFA reauthorization legislation.
The regulator also took issue with how Orexigen Therapeutics presented the risk information
The ad-tax deduction is likely once again on the table.
The former FDA commissioner said marketers need to focus on ensuring that off-label promotion is "non-misleading."
Sandoz counsel argued that Amgen's position "wrongly delays the marketing of every biosimilar."